New drug cocktail aims to delay chemo in metastatic breast cancer
NCT ID NCT03650894
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (nivolumab, bicalutamide, and ipilimumab) in 30 people with advanced HER2-negative breast cancer that has spread. The goal is to see if this chemo-free approach can control the disease for at least 24 weeks. Participants must have measurable tumors and good daily function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Providence Oncology & Hematology Care Clinic - Eastside
Portland, Oregon, 97213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Phone-Based navigation could boost breast cancer detection in kenya
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple